Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1456 Billion KRW | 5.79% |
| 2022 | 1376.37 Billion KRW | 0.64% |
| 2021 | 1367.63 Billion KRW | 8.68% |
| 2020 | 1258.45 Billion KRW | 17.09% |
| 2019 | 1074.73 Billion KRW | 23.33% |
| 2018 | 871.43 Billion KRW | 6.42% |
| 2017 | 818.86 Billion KRW | 16.04% |
| 2016 | 705.66 Billion KRW | 40.85% |
| 2015 | 501 Billion KRW | 65.54% |
| 2014 | 302.65 Billion KRW | 9.06% |
| 2013 | 277.52 Billion KRW | -60.8% |
| 2012 | 708.01 Billion KRW | 4.82% |
| 2011 | 675.48 Billion KRW | 21.96% |
| 2010 | 553.84 Billion KRW | 20.35% |
| 2009 | 460.21 Billion KRW | 2.14% |
| 2008 | 450.56 Billion KRW | 9.36% |
| 2007 | 412.01 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1489.64 Billion KRW | 1.78% |
| 2024 Q1 | 1463.63 Billion KRW | 0.52% |
| 2023 FY | 1456 Billion KRW | 5.79% |
| 2023 Q2 | 1422.64 Billion KRW | 1.5% |
| 2023 Q1 | 1401.62 Billion KRW | 1.83% |
| 2023 Q4 | 1456 Billion KRW | -0.98% |
| 2023 Q3 | 1470.34 Billion KRW | 3.35% |
| 2022 Q1 | 1344.95 Billion KRW | -1.66% |
| 2022 Q2 | 1373.17 Billion KRW | 2.1% |
| 2022 Q4 | 1376.37 Billion KRW | -0.49% |
| 2022 Q3 | 1383.14 Billion KRW | 0.73% |
| 2022 FY | 1376.37 Billion KRW | 0.64% |
| 2021 Q4 | 1367.63 Billion KRW | 1.83% |
| 2021 Q3 | 1343.02 Billion KRW | 5.0% |
| 2021 Q2 | 1279.1 Billion KRW | -0.85% |
| 2021 Q1 | 1290.12 Billion KRW | 2.52% |
| 2021 FY | 1367.63 Billion KRW | 8.68% |
| 2020 Q1 | 1124.71 Billion KRW | 4.65% |
| 2020 Q2 | 1170.76 Billion KRW | 4.09% |
| 2020 FY | 1258.45 Billion KRW | 17.09% |
| 2020 Q3 | 1230.49 Billion KRW | 5.1% |
| 2020 Q4 | 1258.45 Billion KRW | 2.27% |
| 2019 Q2 | 968.82 Billion KRW | 0.8% |
| 2019 FY | 1074.73 Billion KRW | 23.33% |
| 2019 Q4 | 1074.73 Billion KRW | 4.46% |
| 2019 Q1 | 961.15 Billion KRW | 10.3% |
| 2019 Q3 | 1028.87 Billion KRW | 6.2% |
| 2018 FY | 871.43 Billion KRW | 6.42% |
| 2018 Q1 | 843.3 Billion KRW | 2.98% |
| 2018 Q2 | 854.81 Billion KRW | 1.37% |
| 2018 Q3 | 883.35 Billion KRW | 3.34% |
| 2018 Q4 | 871.43 Billion KRW | -1.35% |
| 2017 FY | 818.86 Billion KRW | 16.04% |
| 2017 Q4 | 818.86 Billion KRW | 3.11% |
| 2017 Q3 | 794.13 Billion KRW | 1.27% |
| 2017 Q2 | 784.15 Billion KRW | 0.35% |
| 2017 Q1 | 781.39 Billion KRW | 10.73% |
| 2016 FY | 705.66 Billion KRW | 40.85% |
| 2016 Q4 | 705.66 Billion KRW | 3.3% |
| 2016 Q2 | 509.2 Billion KRW | 0.87% |
| 2016 Q1 | 504.8 Billion KRW | 0.76% |
| 2016 Q3 | 683.11 Billion KRW | 34.15% |
| 2015 FY | 501 Billion KRW | 65.54% |
| 2015 Q4 | 501 Billion KRW | -0.22% |
| 2015 Q3 | 502.1 Billion KRW | -4.43% |
| 2015 Q2 | 525.39 Billion KRW | 68.86% |
| 2015 Q1 | 311.14 Billion KRW | 2.81% |
| 2014 Q4 | 302.65 Billion KRW | 3.07% |
| 2014 FY | 302.65 Billion KRW | 9.06% |
| 2014 Q3 | 293.63 Billion KRW | 3.61% |
| 2014 Q2 | 283.39 Billion KRW | -0.89% |
| 2014 Q1 | 285.94 Billion KRW | 3.03% |
| 2013 Q2 | 715.6 Billion KRW | -0.42% |
| 2013 Q3 | 718.6 Billion KRW | 0.42% |
| 2013 Q4 | 277.52 Billion KRW | -61.38% |
| 2013 FY | 277.52 Billion KRW | -60.8% |
| 2013 Q1 | 718.63 Billion KRW | 1.5% |
| 2012 FY | 708.01 Billion KRW | 4.82% |
| 2012 Q4 | 708.01 Billion KRW | 0.0% |
| 2012 Q1 | 585.79 Billion KRW | 0.0% |
| 2011 Q1 | 550.59 Billion KRW | 0.0% |
| 2011 Q3 | 555.47 Billion KRW | 1.9% |
| 2011 FY | 675.48 Billion KRW | 21.96% |
| 2011 Q2 | 545.1 Billion KRW | -1.0% |
| 2010 Q2 | 444.53 Billion KRW | 2.91% |
| 2010 Q1 | 431.96 Billion KRW | 0.0% |
| 2010 FY | 553.84 Billion KRW | 20.35% |
| 2010 Q3 | 455.23 Billion KRW | 2.41% |
| 2009 Q1 | 368.25 Billion KRW | 0.0% |
| 2009 FY | 460.21 Billion KRW | 2.14% |
| 2009 Q3 | 379.11 Billion KRW | 1.47% |
| 2009 Q2 | 373.61 Billion KRW | 1.46% |
| 2008 Q1 | 338.82 Billion KRW | 0.0% |
| 2008 Q2 | 342.57 Billion KRW | 1.11% |
| 2008 Q3 | 350.47 Billion KRW | 2.31% |
| 2008 FY | 450.56 Billion KRW | 9.36% |
| 2007 Q3 | 337.73 Billion KRW | 0.17% |
| 2007 FY | 412.01 Billion KRW | 0.0% |
| 2007 Q1 | 336.33 Billion KRW | 0.0% |
| 2007 Q2 | 337.17 Billion KRW | 0.25% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -634.563% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 25.604% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -66.021% |
| HANDOK Inc. | 790.33 Billion KRW | -84.225% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -753.361% |
| Yuhan Corporation | 2814.07 Billion KRW | 48.26% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | -10.704% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -1457.572% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 25.411% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -507.308% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -210.513% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -1166.384% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -515.519% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -317.928% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -634.563% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -247.337% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -191.332% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -147.033% |
| JW Holdings Corporation | 1176.26 Billion KRW | -23.782% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -138.197% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | -3.82% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -125.723% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -315.902% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -845.205% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -292.793% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -198.774% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -634.563% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | -35.057% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 17.754% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -125.723% |
| Yuhan Corporation | 2814.07 Billion KRW | 48.26% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | -65.456% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -542.541% |
| Suheung Co., Ltd. | 993.73 Billion KRW | -46.518% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -125.723% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -246.749% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -210.541% |
| CKD Bio Corp. | 293.78 Billion KRW | -395.602% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -186.616% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -157.712% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -262.888% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -315.902% |
| Boryung Corporation | 922.36 Billion KRW | -57.856% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -229.069% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -210.513% |
| JW Lifescience Corporation | 255.83 Billion KRW | -469.115% |